Today-June 10

Next week, 23 healthy volunteers here will be involved in a clinical safety trial for an antibody drug that is hoped to be a viable treatment for patients with Covid-19, a disease that has killed more than 400,000 around the globe so far. Infectious diseases expert Ooi Eng Eong, who co-founded Tychan, the biotech company behind the treatment, told the media in a video conference on Wednesday (June 10) that if trials prove successful, the drug could in future also be used to render temporary protection against infection by the coronavirus, as antibody drugs tend to be effective for about two to three weeks a dose. This being the case, the drug — now known as TY027 — could perhaps be used to protect frontline healthcare workers against any potential exposure of the Sars-CoV-2 coronavirus that causes Covid-19, or travellers when they head to countries with high community transmission of the respiratory disease, he said.

Read more at: https://www.todayonline.com/singapore/singapore-begin-first-human-trial-next-week-potential-covid-19-treatment